Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor

Jennifer D. Stone, Adam S. Chervin, Hans Schreiber, David M Kranz

Research output: Contribution to journalArticle

Abstract

To avoid high systemic doses, strategies involving antigen-specific delivery of cytokine via linked antibodies or antibody fragments have been used. Targeting cancer-associated peptides presented by major histocompatibility complex (MHC) molecules (pepMHC) increases the number of potential target antigens and takes advantage of cross-presentation on tumor stroma and in draining lymph nodes. Here, we use a soluble, high-affinity single-chain T cell receptor Vα-Vβ (scTv), to deliver cytokines to intracellular tumor-associated antigens presented as pepMHC. As typical wild-type T cell receptors (TCRs) exhibit low affinity (Kd = 1-100 μM or more), we used an engineered TCR, m33, that binds its antigenic peptide SIYRYYGL (SIY) bound to the murine class I major histocompatability complex protein H2-Kb (SIY/Kb) with nanomolar affinity (Kd = 30 nM). We generated constructs consisting of m33 scTv fused to murine interleukin 2 (IL-2), interleukin 15 (IL-15), or IL-15/IL-15Rα (IL-15 linked to IL-15Rα sushi domain, called "superfusion"). The fusions were purified with good yields and bound specifically to SIY/Kb with high affinity. Proper cytokine folding and binding were confirmed, and the fusions were capable of stimulating proliferation of cytokine-dependent cells, both when added directly and when presented in trans, bound to cells with the target pepMHC. The m33 superfusion was particularly potent and stable and represents a promising design for targeted antitumor immunomodulation.

Original languageEnglish (US)
Pages (from-to)1588-1597
Number of pages10
JournalBiotechnology Progress
Volume28
Issue number6
DOIs
StatePublished - Nov 1 2012

Fingerprint

Interleukin-15
T-Cell Antigen Receptor
Cytokines
Proteins
Cross-Priming
Antigens
Immunoglobulin Fragments
Peptides
Immunomodulation
Neoplasm Antigens
Major Histocompatibility Complex
Interleukin-2
Neoplasms
Lymph Nodes
Antibodies
superagonist SIYR

Keywords

  • High-affinity TCR
  • IL-15/IL-15Rα
  • IL-2
  • Immunokine
  • TCR-cytokine fusion

ASJC Scopus subject areas

  • Biotechnology

Cite this

Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor. / Stone, Jennifer D.; Chervin, Adam S.; Schreiber, Hans; Kranz, David M.

In: Biotechnology Progress, Vol. 28, No. 6, 01.11.2012, p. 1588-1597.

Research output: Contribution to journalArticle

@article{933dc28423c247d895ba3c3d5985b795,
title = "Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor",
abstract = "To avoid high systemic doses, strategies involving antigen-specific delivery of cytokine via linked antibodies or antibody fragments have been used. Targeting cancer-associated peptides presented by major histocompatibility complex (MHC) molecules (pepMHC) increases the number of potential target antigens and takes advantage of cross-presentation on tumor stroma and in draining lymph nodes. Here, we use a soluble, high-affinity single-chain T cell receptor Vα-Vβ (scTv), to deliver cytokines to intracellular tumor-associated antigens presented as pepMHC. As typical wild-type T cell receptors (TCRs) exhibit low affinity (Kd = 1-100 μM or more), we used an engineered TCR, m33, that binds its antigenic peptide SIYRYYGL (SIY) bound to the murine class I major histocompatability complex protein H2-Kb (SIY/Kb) with nanomolar affinity (Kd = 30 nM). We generated constructs consisting of m33 scTv fused to murine interleukin 2 (IL-2), interleukin 15 (IL-15), or IL-15/IL-15Rα (IL-15 linked to IL-15Rα sushi domain, called {"}superfusion{"}). The fusions were purified with good yields and bound specifically to SIY/Kb with high affinity. Proper cytokine folding and binding were confirmed, and the fusions were capable of stimulating proliferation of cytokine-dependent cells, both when added directly and when presented in trans, bound to cells with the target pepMHC. The m33 superfusion was particularly potent and stable and represents a promising design for targeted antitumor immunomodulation.",
keywords = "High-affinity TCR, IL-15/IL-15Rα, IL-2, Immunokine, TCR-cytokine fusion",
author = "Stone, {Jennifer D.} and Chervin, {Adam S.} and Hans Schreiber and Kranz, {David M}",
year = "2012",
month = "11",
day = "1",
doi = "10.1002/btpr.1631",
language = "English (US)",
volume = "28",
pages = "1588--1597",
journal = "Biotechnology Progress",
issn = "8756-7938",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Design and characterization of a protein superagonist of IL-15 fused with IL-15Rα and a high-affinity T cell receptor

AU - Stone, Jennifer D.

AU - Chervin, Adam S.

AU - Schreiber, Hans

AU - Kranz, David M

PY - 2012/11/1

Y1 - 2012/11/1

N2 - To avoid high systemic doses, strategies involving antigen-specific delivery of cytokine via linked antibodies or antibody fragments have been used. Targeting cancer-associated peptides presented by major histocompatibility complex (MHC) molecules (pepMHC) increases the number of potential target antigens and takes advantage of cross-presentation on tumor stroma and in draining lymph nodes. Here, we use a soluble, high-affinity single-chain T cell receptor Vα-Vβ (scTv), to deliver cytokines to intracellular tumor-associated antigens presented as pepMHC. As typical wild-type T cell receptors (TCRs) exhibit low affinity (Kd = 1-100 μM or more), we used an engineered TCR, m33, that binds its antigenic peptide SIYRYYGL (SIY) bound to the murine class I major histocompatability complex protein H2-Kb (SIY/Kb) with nanomolar affinity (Kd = 30 nM). We generated constructs consisting of m33 scTv fused to murine interleukin 2 (IL-2), interleukin 15 (IL-15), or IL-15/IL-15Rα (IL-15 linked to IL-15Rα sushi domain, called "superfusion"). The fusions were purified with good yields and bound specifically to SIY/Kb with high affinity. Proper cytokine folding and binding were confirmed, and the fusions were capable of stimulating proliferation of cytokine-dependent cells, both when added directly and when presented in trans, bound to cells with the target pepMHC. The m33 superfusion was particularly potent and stable and represents a promising design for targeted antitumor immunomodulation.

AB - To avoid high systemic doses, strategies involving antigen-specific delivery of cytokine via linked antibodies or antibody fragments have been used. Targeting cancer-associated peptides presented by major histocompatibility complex (MHC) molecules (pepMHC) increases the number of potential target antigens and takes advantage of cross-presentation on tumor stroma and in draining lymph nodes. Here, we use a soluble, high-affinity single-chain T cell receptor Vα-Vβ (scTv), to deliver cytokines to intracellular tumor-associated antigens presented as pepMHC. As typical wild-type T cell receptors (TCRs) exhibit low affinity (Kd = 1-100 μM or more), we used an engineered TCR, m33, that binds its antigenic peptide SIYRYYGL (SIY) bound to the murine class I major histocompatability complex protein H2-Kb (SIY/Kb) with nanomolar affinity (Kd = 30 nM). We generated constructs consisting of m33 scTv fused to murine interleukin 2 (IL-2), interleukin 15 (IL-15), or IL-15/IL-15Rα (IL-15 linked to IL-15Rα sushi domain, called "superfusion"). The fusions were purified with good yields and bound specifically to SIY/Kb with high affinity. Proper cytokine folding and binding were confirmed, and the fusions were capable of stimulating proliferation of cytokine-dependent cells, both when added directly and when presented in trans, bound to cells with the target pepMHC. The m33 superfusion was particularly potent and stable and represents a promising design for targeted antitumor immunomodulation.

KW - High-affinity TCR

KW - IL-15/IL-15Rα

KW - IL-2

KW - Immunokine

KW - TCR-cytokine fusion

UR - http://www.scopus.com/inward/record.url?scp=84872399679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872399679&partnerID=8YFLogxK

U2 - 10.1002/btpr.1631

DO - 10.1002/btpr.1631

M3 - Article

VL - 28

SP - 1588

EP - 1597

JO - Biotechnology Progress

JF - Biotechnology Progress

SN - 8756-7938

IS - 6

ER -